CPA
ACRV icon

Capital Performance Advisors’s Acrivon Therapeutics ACRV Stock Holding History

Capital Performance Advisors’s Portfolio ACRV Stock Details ACRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-32
Closed -$224 – 200
2024
Q3 		$224 Buy
+32
New +$252 ﹤0.01% 2530

Other funds holding ACRV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Performance Advisors's ACRV Position: Q4 2024 in Review

Capital Performance Advisors sold out of Acrivon Therapeutics (ACRV) in Q4 2024, closing a stake of 32 shares — an estimated $224 sold.

Capital Performance Advisors first reported a position in ACRV in Q3 2024 and held it in 1 quarter. The position peaked at $224 in Q3 2024. 63 funds tracked by Wall St. Rank hold ACRV as of Q4 2024.

  • Capital Performance Advisors reported no remaining Acrivon Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 32 Acrivon Therapeutics shares in Q4 2024, an estimated $224.
  • Capital Performance Advisors first reported a position in Acrivon Therapeutics in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Acrivon Therapeutics position peaked at $224 in Q3 2024.
  • 63 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.